No immunity for Dendreon’s cancer vaccine
(UPDATED: See below.) For almost two months, it has seemed that the FDA might be ready to approve an entirely new attack on cancer — a “cancer vaccine” that immunizes patients with tumor fragments in order to activate the body’s immune defenses against cancerous cells.
That dream suffered a major setback earlier today, when the FDA threw up a fresh roadblock to the approval of Dendreon’s Provenge, the first such cancer vaccine to go before the agency… Continue Reading